[Prevention of arrhythmias and cardiac fibrillation in acute ischemia and reperfusion by using a factor causing GABA accumulation in the brain].
Anticonvulsant sodium valproate, an inhibitor of GABA transaminase, which induces GABA accumulation in the brain, has been shown to possess a potent antiarrhythmic effect. In acute ischemia and reperfusion in conscious rats with closed chest, it decreased fourfold total duration of arrhythmias, while in nonanesthetized animals with open chest, it substantially limited the heart electrical fibrillation threshold and reduced fourfold total duration of arrhythmias. In both experimental models, sodium valproate decreased threefold the rate of ischemia-induced heart fibrillations. Clinicophysiological evaluation of the effect of sodium valproate on arrhythmias in coronary patients appears warranted.
D000208:Acute Disease; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000517:prevention & control*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D014635:Valproic Acid / Q000627:therapeutic use*; D014693:Ventricular Fibrillation / Q000209:etiology / Q000517:prevention & control*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid
Preduprezhdenie aritmiĭ i fibrilliatsii serdtsa pri ostroĭ ishemii i reperfuzii s pomoshch'iu faktora, vyzyvaiushchego nakoplenie GAMK v golovnom mozge.